Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

Shruti Gupta¹, Ian A Strohbehn², Qiyu Wang², Paul E Hanna², Rituvanthikaa Seethapathy², Jason M Prosek³, Sandra M Herrmann⁴, Ala Abudayyeh⁵, A Bilal Malik⁶, Sebastian Loew⁷, Christopher A Carlos⁸, Wei-Ting Chang⁹, Pazit Beckerman¹⁰, Zain Mithani¹¹, Chintan V Shah¹², Amanda D Renaghan¹³, Sophie de Seigneux¹⁴, Luca Campedel¹⁵, Abhijat Kitchlu¹⁶, Daniel Sanghoon Shin¹⁷, Gaia Coppock¹⁸, Nuttha Lumlertgul¹⁹, Pablo Garcia²⁰, David I Ortiz-Melo²¹, Arash Rashidi²², Ben Sprangers²³, Vikram Aggarwal²⁴, Karolina Benesova²⁵, Kenar D Jhaveri²⁶, Frank B Cortazar²⁷, Astrid Weins²⁸, Yiqin Zuo²⁹, Meghan J Mooradian³⁰, Kerry L Reynolds³⁰, David E Leaf¹, Meghan E Sise³¹; ICPi-AKI Consortium

Collaborators, Affiliations

Collaborators

ICPi-AKI Consortium:
Luca Campedel, Joe-Elie Salem, Corinne Isnard Bagnis, Shruti Gupta, David E Leaf, Harkarandeep Singh, Shveta S Motwani, Naoka Murakami, Maria C Tio, Suraj S Mothi, Umut Selamet, Astrid Weins, Sebastian Loew, Kai M Schmidt-Ott, Weiting Chang, Kenar D Jhaveri, Rimda Wanchoo, Yuriy Khanin, Jamie S Hirsch, Vipulbhai Sakhiya, Daniel Stalbow, Sylvia Wu, David I Ortiz-Melo, Marlies Ostermann, Nuttha Lumlertgul, Nina Seylanova, Armando Cennamo, Anne Rigg, Nisha Shaunak, Zoe A Kibbelaar, Karolina Benesova, Priya Deshpande, Meghan E Sise, Kerry L Reynolds, Harish S Seethapathy, Meghan Lee, Ian A Strohbhen, Meghan J Mooradian, Paul E Hanna, Qiyu Wang, Rituvanthikaa Seethapathy, Sandra M Herrmann, Busra Isik, Ilya G Glezerman, Frank B Cortazar, Vikram Aggarwal, Sunandana Chandra, Jason M Prosek, Sethu M Madhavan, Dwight H Owen, Marium Husain, Pazit Beckerman, Sharon Mini, Shuchi Anand, Pablo Garcia, Aydin Kaghazchi, Sunil Rangarajan, Daniel Sanghoon Shin, Grace Cherry, Christopher A Carlos, Raymond K Hsu, Andrey Kisel, Arash Rashidi, Sheru K Kansal, Nicole Albert, Katherine Carter, Vicki Donley, Tricia Young, Heather Cigoi, Sophie De Seigneux, Thibaud Koessler, Ben Sprangers, Els Wauters, Chintan V Shah, Mark Eijgelsheim, Zain Mithani, Javier A Pagan, Yiqin Zuo, Gaia Coppock, Jonathan J Hogan, Ala Abudayyeh, Omar Mamlouk, Jamie S Lin, Valda Page, Abhijat Kitchlu, Samuel A P Short, Amanda D Renaghan, Elizabeth M Gaughan, A Bilal Malik, Maria Jose Soler, Clara García-Carro, Sheila Bermejo, Enriqueta Felip, Eva Muñoz-Couselo, Maria Josep Carreras

Affiliations

¹ Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
² Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
³ Division of Nephrology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio, USA.
⁴ Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
⁵ Division of Internal Medicine, Section of Nephrology, the University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁶ Division of Nephrology, University of Washington, Seattle, Washington, USA.
⁷ Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany.
⁸ Department of Medicine, Division of Nephrology, University of California San Francisco, San Francisco, California, USA.
⁹ Department of Clinical Medicine, Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Internal Medicine, Division of Cardiology, Chi-Mei Medical Center, Tainan, Taiwan; Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan.
¹⁰ Institute of Nephrology and Hypertension, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.
¹¹ Katz Family Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, Florida, USA.
¹² Department of Medicine, Division of Nephrology, Hypertension, and Renal Transplant, University of Florida, Gainesville, Florida, USA.
¹³ Division of Nephrology, University of Virginia Health System, Charlottesville, Virginia, USA.
¹⁴ Service of Nephrology, Department of Medicine, University Hospital of Geneva, Geneva, Switzerland.
¹⁵ Department of Medical Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Hôpital Pitié-Salpêtrière, Institut universitaire de cancérologie, CLIP Galilée, Groupe de Recherche Interdisciplinaire Francophone en Onco-néphrologie (GRIFON), Paris, France.
¹⁶ Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
¹⁷ Department of Medicine, Division of Hematology-Oncology, Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS), David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California, USA.
¹⁸ Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁹ Department of Critical Care, Guy's & St Thomas Hospital, London, UK; Division of Nephrology, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
²⁰ Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA.
²¹ Division of Nephrology, Duke University Medical Center, Durham, North Carolina, USA.
²² Division of Nephrology and Hypertension, University Hospital Cleveland Medical Center, Cleveland, Ohio, USA.
²³ Department of Microbiology, Immunology and Transplantation, Laboratory of Molecular Immunology (Rega Institute for Medical Research), KU Leuven, Leuven, Belgium; Division of Nephrology, University Hospitals Leuven, Leuven, Belgium.
²⁴ Department of Nephrology and Hypertension, Northwestern University and Feinberg School of Medicine, Chicago, Illinois, USA.
²⁵ Department of Medicine V, Hematology, Oncology, and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
²⁶ Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Great Neck, New York, USA.
²⁷ New York Nephrology Vasculitis and Glomerular Center, Albany, New York, USA.
²⁸ Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
²⁹ Department of Pathology and Laboratory Medicine, University of Miami, Miami, Florida, USA.
³⁰ Division of Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
³¹ Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: msise@partners.org.

PMID: 35964800
PMCID: PMC9523226
DOI: 10.1016/j.kint.2022.07.019

Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

Shruti Gupta et al. Kidney Int. 2022 Oct.

. 2022 Oct;102(4):930-935.

doi: 10.1016/j.kint.2022.07.019. Epub 2022 Aug 11.

Authors

Collaborators

ICPi-AKI Consortium:
Luca Campedel, Joe-Elie Salem, Corinne Isnard Bagnis, Shruti Gupta, David E Leaf, Harkarandeep Singh, Shveta S Motwani, Naoka Murakami, Maria C Tio, Suraj S Mothi, Umut Selamet, Astrid Weins, Sebastian Loew, Kai M Schmidt-Ott, Weiting Chang, Kenar D Jhaveri, Rimda Wanchoo, Yuriy Khanin, Jamie S Hirsch, Vipulbhai Sakhiya, Daniel Stalbow, Sylvia Wu, David I Ortiz-Melo, Marlies Ostermann, Nuttha Lumlertgul, Nina Seylanova, Armando Cennamo, Anne Rigg, Nisha Shaunak, Zoe A Kibbelaar, Karolina Benesova, Priya Deshpande, Meghan E Sise, Kerry L Reynolds, Harish S Seethapathy, Meghan Lee, Ian A Strohbhen, Meghan J Mooradian, Paul E Hanna, Qiyu Wang, Rituvanthikaa Seethapathy, Sandra M Herrmann, Busra Isik, Ilya G Glezerman, Frank B Cortazar, Vikram Aggarwal, Sunandana Chandra, Jason M Prosek, Sethu M Madhavan, Dwight H Owen, Marium Husain, Pazit Beckerman, Sharon Mini, Shuchi Anand, Pablo Garcia, Aydin Kaghazchi, Sunil Rangarajan, Daniel Sanghoon Shin, Grace Cherry, Christopher A Carlos, Raymond K Hsu, Andrey Kisel, Arash Rashidi, Sheru K Kansal, Nicole Albert, Katherine Carter, Vicki Donley, Tricia Young, Heather Cigoi, Sophie De Seigneux, Thibaud Koessler, Ben Sprangers, Els Wauters, Chintan V Shah, Mark Eijgelsheim, Zain Mithani, Javier A Pagan, Yiqin Zuo, Gaia Coppock, Jonathan J Hogan, Ala Abudayyeh, Omar Mamlouk, Jamie S Lin, Valda Page, Abhijat Kitchlu, Samuel A P Short, Amanda D Renaghan, Elizabeth M Gaughan, A Bilal Malik, Maria Jose Soler, Clara García-Carro, Sheila Bermejo, Enriqueta Felip, Eva Muñoz-Couselo, Maria Josep Carreras

Affiliations

¹ Division of Renal Medicine, Brigham and Women's Hospital, Boston, Massachusetts, USA.
² Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA.
³ Division of Nephrology, Department of Internal Medicine, the Ohio State University, Columbus, Ohio, USA.
⁴ Division of Nephrology and Hypertension, Mayo Clinic, Rochester, Minnesota, USA.
⁵ Division of Internal Medicine, Section of Nephrology, the University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
⁶ Division of Nephrology, University of Washington, Seattle, Washington, USA.
⁷ Department of Nephrology and Medical Intensive Care, Charité-Universitätsmedizin Berlin, Berlin, Germany.
⁸ Department of Medicine, Division of Nephrology, University of California San Francisco, San Francisco, California, USA.
⁹ Department of Clinical Medicine, Institute of Clinical Medicine, College of Medicine, National Cheng Kung University, Tainan, Taiwan; Department of Internal Medicine, Division of Cardiology, Chi-Mei Medical Center, Tainan, Taiwan; Department of Biotechnology, Southern Taiwan University of Science and Technology, Tainan, Taiwan.
¹⁰ Institute of Nephrology and Hypertension, Sheba Medical Center and Sackler School of Medicine, Tel Aviv University, Tel Aviv-Yafo, Israel.
¹¹ Katz Family Division of Nephrology and Hypertension, University of Miami Miller School of Medicine, Miami, Florida, USA.
¹² Department of Medicine, Division of Nephrology, Hypertension, and Renal Transplant, University of Florida, Gainesville, Florida, USA.
¹³ Division of Nephrology, University of Virginia Health System, Charlottesville, Virginia, USA.
¹⁴ Service of Nephrology, Department of Medicine, University Hospital of Geneva, Geneva, Switzerland.
¹⁵ Department of Medical Oncology, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Hôpital Pitié-Salpêtrière, Institut universitaire de cancérologie, CLIP Galilée, Groupe de Recherche Interdisciplinaire Francophone en Onco-néphrologie (GRIFON), Paris, France.
¹⁶ Division of Nephrology, University Health Network, University of Toronto, Toronto, Ontario, Canada.
¹⁷ Department of Medicine, Division of Hematology-Oncology, Veterans Affairs Greater Los Angeles Healthcare System (VAGLAHS), David Geffen School of Medicine at University of California-Los Angeles, Los Angeles, California, USA.
¹⁸ Renal-Electrolyte and Hypertension Division, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
¹⁹ Department of Critical Care, Guy's & St Thomas Hospital, London, UK; Division of Nephrology, Faculty of Medicine, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
²⁰ Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA.
²¹ Division of Nephrology, Duke University Medical Center, Durham, North Carolina, USA.
²² Division of Nephrology and Hypertension, University Hospital Cleveland Medical Center, Cleveland, Ohio, USA.
²³ Department of Microbiology, Immunology and Transplantation, Laboratory of Molecular Immunology (Rega Institute for Medical Research), KU Leuven, Leuven, Belgium; Division of Nephrology, University Hospitals Leuven, Leuven, Belgium.
²⁴ Department of Nephrology and Hypertension, Northwestern University and Feinberg School of Medicine, Chicago, Illinois, USA.
²⁵ Department of Medicine V, Hematology, Oncology, and Rheumatology, University Hospital Heidelberg, Heidelberg, Germany.
²⁶ Division of Kidney Diseases and Hypertension, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Northwell Health, Great Neck, New York, USA.
²⁷ New York Nephrology Vasculitis and Glomerular Center, Albany, New York, USA.
²⁸ Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
²⁹ Department of Pathology and Laboratory Medicine, University of Miami, Miami, Florida, USA.
³⁰ Division of Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
³¹ Division of Nephrology, Massachusetts General Hospital, Boston, Massachusetts, USA. Electronic address: msise@partners.org.

PMID: 35964800
PMCID: PMC9523226
DOI: 10.1016/j.kint.2022.07.019

No abstract available

PubMed Disclaimer

Figures

Figure 1 |. (a) Massachusetts General Brigham (MGB) cohort study with acute kidney injury (AKI) rates (any AKI incidence and breakdown of stages 1–3); (b) breakdown of the AKI stage in the immune checkpoint inhibitor-associated acute kidney injury (ICPi-AKI) cohort study; (c) AKI recovery rates in the MGB cohort; (d) AKI recovery rates in the ICPi-AKI cohort.
In the ICPi-AKI cohort, there was 1 patient in the triplet therapy group who received kidney replacement therapy (KRT) (4.4%) and was ultimately liberated from KRT, as compared with 2 patients in the pembrolizumab monotherapy group (5.0%) who received KRT, 1 of whom was liberated from KRT. In the MGB cohort, 2 patients received KRT, and neither was liberated from KRT.

See this image and copyright information in PMC

References

1. Gandhi L, Rodríguez-Abreu D, Gadgeel S, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. N Engl J Med. 2018;378:2078–2092. - PubMed
1. Gupta S, Short SAP, Sise ME, et al. Acute kidney injury in patients treated with immune checkpoint inhibitors. J Immunother Cancer. 2021;9: e003467. - PMC - PubMed
1. Glezerman IG, Pietanza MC, Miller V, Seshan SV. Kidney tubular toxicity of maintenance pemetrexed therapy. Am J Kidney Dis. 2011;58: 817–820. - PubMed
1. Visser S, Huisbrink J, van ‘t Veer NE, et al. Renal impairment during pemetrexed maintenance in patients with advanced nonsmall cell lung cancer: a cohort study. Eur Respir J. 2018;52:1800884. - PubMed
1. Motwani SS, McMahon GM, Humphreys BD, et al. Development and validation of a risk prediction model for acute kidney injury after the first course of cisplatin. J Clin Oncol. 2018;36:682–688. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

Collaborators

Affiliations

Acute kidney injury in patients receiving pembrolizumab combination therapy versus pembrolizumab monotherapy for advanced lung cancer

Authors

Collaborators

Affiliations

Figures

References

Publication types

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical